In 2021, Medicilon established the International Discovery Service Unit (IDSU) to provide global pharmaceutical companies with high quality, high efficient and cost-effective chemistry synthesis design and production, medicinal chemistry, and the discovery and project delivery of clinical candidate compounds, which empowering global drug research and development.
In the past two years, the Medicilon’ IDSU has been constantly empowering and accumulating momentum, striving to promote the leap from quantitative accumulation to qualitative, and to be at the forefront of new technologies in global drug design and synthesis. Medicilon actively develops and introduces artificial intelligence/machine learning (AI/ML), protein degradation targeting chimera (PROTAC), highly active drugs and antibody drug conjugates (ADC), direct functionalization of inert carbon-hydrogen bonds, photoredox reactions, as well as the development of new technologies such as flow chemistry, leading the new trend of global drug discovery.
March 8 Special Project of Medicilon. More [her] through their efforts to promote gender equality with innovation and technology, the world sees more possibilities.
This time, Medicilon, with three women female scientists, tell you about their scientific research strength.
By the end of 2022, Medicilon will have 1688 female employees. Break the prejudice， and promote gender equality with innovation and technology. We're in action.
